New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:17 EDTMDTMedtronic's SYMPLICITY HTN-3 trial fails to meet primary efficacy endpoint
Medtronic announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board concluded that there were no safety concerns in the study. Based on these clinical trial findings, Medtronic intends to formulate a panel of independent advisors made up of physicians and researchers who will be asked to make recommendations about the future of the global hypertension clinical trial program, as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals.
News For MDT From The Last 14 Days
Check below for free stories on MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
06:30 EDTMDTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
July 21, 2014
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 16, 2014
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 14, 2014
07:12 EDTMDTCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use